Lactobacillus casei modulates the inflammation-coagulation interaction in a pneumococcal pneumonia experimental model

Haro, Cecilia; Villena, Julio; Zelaya, Hortensia; Alvarez, Susana; Agüero, Graciela

doi:10.1186/1476-9255-6-28

Cited by 27 publications

(21 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, it has been reported that some types for probiotic bacteria influence markers of coagulation in a beneficial manner (38). However, we found no effect of Cardi04 yogurt on any of the key markers of coagulation measured in this study.…”

Section: Discussioncontrasting

confidence: 56%

Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study

Hove

Brøns

Færch

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Studies have indicated a blood pressure (BP)-lowering effect of milk-derived peptides in non-diabetic individuals, but the cardiometabolic effects of such peptides in patients with type 2 diabetes (T2D) are not known. We investigated the effect of milk fermented with Lactobacillus helveticus on BP, glycaemic control and cardiovascular risk factors in T2D. Design: A randomised, double-blinded, prospective, placebo-controlled study. Methods: In one arm of a factorial study design, 41 patients with T2D were randomised to receive 300 ml milk fermented with L. helveticus (Cardi04 yogurt) (nZ23) or 300 ml artificially acidified milk (placebo yogurt) (nZ18) for 12 weeks. BPs were measured over 24-h, and blood samples were collected in the fasting state and during a meal test before and after the intervention. Results: Cardi04 yogurt did not reduce 24-h, daytime or nighttime systolic or diastolic BPs compared with placebo (PO0.05). Daytime and 24-h heart rate (HR) were significantly reduced in the group treated by Cardi04 yogurt compared with the placebo group (P!0.05 for both). There were no differences in HbA1c, plasma lipids, C-reactive protein, plasminogen activator inhibitor-1, tumour necrosis factor alpha, tissue-type plasminogen activator: Ag, and von Willebrand factor: Ag between the groups. The change in fasting blood glucose concentration differed significantly between the two groups with a larger increase in the placebo group (P!0.05). Conclusions: Ingestion of milk fermented with L. helveticus compared with placebo for 12 weeks did not significantly reduce BP in patients with T2D. Our finding of lower HRs and fasting plasma glucose levels in T2D patients during ingestion of fermented milk needs further validation.

show abstract

Section: Discussioncontrasting

confidence: 56%

Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study

Hove

Brøns

Færch

et al. 2015

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…This suggests that the enhancement of plasmin activity by lactobacilli remains local and could function, e.g., to contribute to the dissolution of fibrin clots or thrombi over a wound site. Along these lines, it was reported previously that the treatment of mice suffering from pneumococcal pneumonia with Lactobacillus casei lowers the amount of fibrin(ogen) deposits in the lung (1,22), and the potential of synbiotics to reduce procoagulatory factors has been recognized (8). The mechanisms of these in vivo effects obviously are complex, but our results encourage further studies of the role and the mechanisms of the modulation of the fibrinolysis/coagulation cascades by commensal bacteria.…”

Section: Discussionmentioning

confidence: 73%

Glutamine Synthetase and Glucose-6-Phosphate Isomerase Are Adhesive Moonlighting Proteins of Lactobacillus crispatus Released by Epithelial Cathelicidin LL-37

Kainulainen

Loimaranta

Pekkala

et al. 2012

Journal of Bacteriology

View full text Add to dashboard Cite

c Glutamine synthetase (GS) and glucose-6-phosphate isomerase (GPI) were identified as novel adhesive moonlighting proteins of Lactobacillus crispatus ST1. Both proteins were bound onto the bacterial surface at acidic pHs, whereas a suspension of the cells to pH 8 caused their release into the buffer, a pattern previously observed with surface-bound enolase and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) of L. crispatus. The pH shift was associated with a rapid and transient increase in cell wall permeability, as measured by cell staining with propidium iodide. A gradual increase in the release of the four moonlighting proteins was also observed after the treatment of L. crispatus ST1 cells with increasing concentrations of the antimicrobial cationic peptide LL-37, which kills bacteria by disturbing membrane integrity and was here observed to increase the cell wall permeability of L. crispatus ST1. At pH 4, the fusion proteins His 6 -GS, His 6 -GPI, His 6 -enolase, and His 6 -GAPDH showed localized binding to cell division septa and poles of L. crispatus ST1 cells, whereas no binding to Lactobacillus rhamnosus GG was detected. Strain ST1 showed a pH-dependent adherence to the basement membrane preparation Matrigel. Purified His 6 -GS and His 6 -GPI proteins bound to type I collagen, and His 6 -GS also bound to laminin, and their level of binding was higher at pH 5.5 than at pH 6.5. His 6 -GS also expressed a plasminogen receptor function. The results show the strain-dependent surface association of moonlighting proteins in lactobacilli and that these proteins are released from the L. crispatus surface after cell trauma, under conditions of alkaline stress, or in the presence of the antimicrobial peptide LL-37 produced by human cells.

show abstract

“…Even though it is beneficial in most cases, it has also been associated with endocarditis (24), pulmonary abscess, and pleuritis (25). Lactobacillus casei was found to have a protective role in the lung of a mouse model during Streptococcus pneumoniae infection (26). In patient CF8, the presence of Lactobacillus spp.…”

Section: Discussionmentioning

confidence: 99%

Clinical Insights from Metagenomic Analysis of Sputum Samples from Patients with Cystic Fibrosis

et al. 2014

View full text Add to dashboard Cite

f As DNA sequencing becomes faster and cheaper, genomics-based approaches are being explored for their use in personalized diagnoses and treatments. Here, we provide a proof of principle for disease monitoring using personal metagenomic sequencing and traditional clinical microbiology by focusing on three adults with cystic fibrosis (CF). The CF lung is a dynamic environment that hosts a complex ecosystem composed of bacteria, viruses, and fungi that can vary in space and time. Not surprisingly, the microbiome data from the induced sputum samples we collected revealed a significant amount of species diversity not seen in routine clinical laboratory cultures. The relative abundances of several species changed as clinical treatment was altered, enabling the identification of the climax and attack communities that were proposed in an earlier work. All patient microbiomes encoded a diversity of mechanisms to resist antibiotics, consistent with the characteristics of multidrug-resistant microbial communities that are commonly observed in CF patients. The metabolic potentials of these communities differed by the health status and recovery route of each patient. Thus, this pilot study provides an example of how metagenomic data might be used with clinical assessments for the development of treatments tailored to individual patients.

show abstract

Lactobacillus casei modulates the inflammation-coagulation interaction in a pneumococcal pneumonia experimental model

Abstract: Background: We have previously demonstrated that Lactobacillus casei CRL 431 administration improved the resistance to pneumococcal infection in a mouse model.

Cited by 27 publications

References 30 publications

Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study

Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study

Glutamine Synthetase and Glucose-6-Phosphate Isomerase Are Adhesive Moonlighting Proteins of Lactobacillus crispatus Released by Epithelial Cathelicidin LL-37

Clinical Insights from Metagenomic Analysis of Sputum Samples from Patients with Cystic Fibrosis

Contact Info

Product

Resources

About